O
Oncolytics Biotech Inc. (ONCY)
NCM – Real vaqt narxi. Valyuta: USD
0.90
-0.00 (-0.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.92
+0.02 (1.85%)
Bozor oldidan: May 13, 2026, 6:20 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
0.90
-0.00 (-0.03%)
Yopilishda: May 12, 2026, 4:00 PM EDT
0.92
+0.02 (1.85%)
Bozor oldidan: May 13, 2026, 6:20 AM EDT
Oncolytics Biotech Inc., klinik bosqichdagi biopartiya kompaniyasi, onkologik davolashni tadqiq qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniya oshqozon-ichak ("GI") o'smalari, metastatik kolorektal saraton, anal saraton va metastatik oshqozon osti bezi saratonini davolash uchun tomir ichiga yuboriladigan immunoterapiya vositasi pelareorepni ishlab chiqadi. Uning Roche Holding AG bilan o'tkazilayotgan homiylik tadqiqotlarida foydalanish uchun immunitet nazorat nuqtasi ingibitorlari, atezolizumabni ta'minlash bo'yicha kelishuvi mavjud. Oncolytics Biotech Inc. 1998 yilda tashkil etilgan va San-Diegoda, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Thomas C. Heineman M.D., Ph.D. | Chief Medical Officer |
| Jon Patton | Director of Investor Relations & Communication |
| Mr. Andrew P. Aromando | Chief Business Officer |
| Mr. Jared Kelly J.D., L.L.M. | CEO & Director |
| Mr. John McAdory | Executive VP of Strategy & Operations |
| Mr. John Mark Lievonen B.B.A., CM, F.C.A., FCPA, LLD, M.B.A. | Consultant |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | 8-K | oncy-20260504.htm |
| 2026-04-27 | 8-K | oncy-20260427.htm |
| 2026-04-08 | F-10POS | tm2610715d24_f10pos.htm |
| 2026-04-08 | AW | tm2610715d33_aw.htm |
| 2026-04-06 | F-10POS | tm2610715-8_f10pos.htm |
| 2026-04-06 | 8-K | tm2610715d2_8k.htm |
| 2026-04-01 | POS AM | tm2610685d1_posam.htm |
| 2026-04-01 | F-10POS | tm2610685d13_f10pos.htm |
| 2026-04-01 | CORRESP | filename1.htm |
| 2026-03-30 | 10-K | oncy-20251231.htm |
| Mr. Kirk J. Look C.A., CPA | Chief Financial Officer |
| Ms. Allison Hagerman P.Eng., P.M.P. | Chief Technology Officer |
| Yujun Wu | VP & Head of Biostatistics |